The physicians contacted defended the use of the drug, but they were also paid by 
Pfizer to participate in the study. This appears to be another controversial case whereby use from the public is in conflict with physician reports, which is becoming more common place today to have both areas of input available. I guess we may not know more until additional data and information is analyzed for a more conclusive report, and that could be a while before it’s available. Hopefully when the FDA is set up to mine additional data sources, this information might make it’s way to the forefront a little faster in the future. BD
The FDA has been taking a close look at the reports of adverse events that have been coming in," said FDA spokesperson Susan Cruzan. She added that any study done by Pfizer on Chantix would have had to have been sent to the FDA for review at the time that it was published, according to FDA policy regarding studies done by drug manufacturers.And he says that the lack of response to his concerns by Pfizer and the FDA underscores what could be a hidden public health threat when it comes to drug safety."It turned out my only recourse was a letter to the editor in an obscure journal with no press coverage," Spangler says. "It's wrong, because I turned out to be right.
0 comments :
Post a Comment